Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many
people perceive breast cancer to be the number one threat to women's health. CVD and …

Every year, more than 2 million women worldwide are diagnosed with breast or cervical
cancer, yet where a woman lives, her socioeconomic status, and agency largely determines …

In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …

Purpose To update the ASCO clinical practice guideline on adjuvant endocrine therapy
based on emerging data about the optimal duration of aromatase inhibitor (AI) treatment …

The purpose of the American Cancer Society/American Society of Clinical Oncology Breast
Cancer Survivorship Care Guideline is to provide recommendations to assist primary care …

In 2012, the estimated age-adjusted annual incidence of breast cancer in 40 European
countries was 94.2/100 000 and the mortality 23.1/100 000 [1]. The incidence increased …

Estrogen receptor alpha (ERα) has been recognized now for several decades as playing a
key role in reproduction and exerting functions in numerous nonreproductive tissues. In this …

Purpose To update the ASCO clinical practice guideline on adjuvant endocrine therapy on
the basis of emerging data on the optimal duration of treatment, particularly adjuvant …

Background Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared
with tamoxifen, in postmenopausal women with hormone-receptor–positive breast cancer …

Importance Estrogen receptor–positive (ER+) tumors of the breast are generally highly
responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant …